Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03141671 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
A Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
- 8
- Study locations
NCT03141671 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 345 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT03141671, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Bicalutamide
- DRUG GnRH
- RADIATION Salvage radiation
Study Locations (8)
California
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute/Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03141671
The ClinicalTrials.gov registry entry for NCT03141671 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (43% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.
NCT03141671 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT03141671 about?
NCT03141671 is a clinical study titled "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)". This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
What is the current status of trial NCT03141671?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2017-11-24. Estimated completion is 2025-12-31.
What conditions does trial NCT03141671 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03141671?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), Bicalutamide (DRUG), GnRH (DRUG), Salvage radiation (RADIATION).
Who is sponsoring clinical trial NCT03141671?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03141671 being conducted?
This trial has 8 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.